ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

SNGX Soligenix Inc

4.24
0.42 (10.99%)
Jun 18 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Soligenix Inc SNGX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.42 10.99% 4.24 19:00:00
Open Price Low Price High Price Close Price Previous Close
3.81 3.81 4.28 4.24 3.82
more quote information »

Recent News

Date Time Source Heading
6/14/202406:30PRNUSA Comparison of Vaccine Technologies to be Presented at the..
6/05/202407:00GLOBESetting the Stage for Success: PRISM MarketView Highlights..
5/31/202407:00EDGAR2Form 8-K - Current report
5/31/202406:30PRNUSSoligenix Announces Reverse Stock Split
5/29/202415:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
5/29/202406:30PRNUSSoligenix Encourages Stockholders to Vote their Shares at..
5/28/202415:08EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
5/24/202415:05EDGAR2Form 8-K - Current report
5/24/202406:30PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
5/23/202406:30PRNUSSoligenix Encourages Stockholders to Vote "FOR" Reverse..
5/22/202415:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
5/21/202411:35GLOBEPRISM MarketView Highlights Soligenix, Inc. as it Builds on..
5/21/202406:30PRNUSSuVax™ and MarVax™ Thermostable Vaccine Platform to be..
5/20/202406:30PRNUSSoligenix Encourages Stockholders to Vote Prior to Annual..
5/17/202415:25EDGAR2Form 8-K - Current report
5/17/202415:09EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
5/16/202406:30PRNUSPositive Clinical Results from HyBryte™ Compatibility Study..
5/15/202415:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
5/10/202415:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
5/10/202415:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/10/202406:30PRNUSSoligenix Announces Recent Accomplishments And First Quarter..
5/06/202406:30PRNUSSoligenix to Present at Upcoming Conferences
4/25/202406:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
4/18/202407:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
4/15/202406:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
4/11/202406:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
4/03/202406:30PRNUSSoligenix Announces Agreement on the Design of a Second..
3/15/202406:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
2/08/202406:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
1/25/202406:30PRNUSSoligenix to Present at The Microcap Conference
1/08/202406:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
1/04/202406:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
1/02/202406:30PRNUSSoligenix Announces Publication Demonstrating Complete..
12/22/202315:05EDGAR2Form 8-K - Current report
12/17/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
12/15/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/15/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/15/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/15/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/15/202315:03EDGAR2Form 8-K - Current report
12/08/202316:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/08/202316:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/08/202316:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/08/202316:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/08/202315:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
12/01/202306:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
11/30/202306:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
11/17/202315:05EDGAR2Form 8-K - Current report
11/17/202315:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
11/13/202315:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]